Spot Trading’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$3.47M Buy
76,400
+54,900
+255% +$2.19M 0.06% 438
2017
Q2
$725K Buy
21,500
+11,900
+124% +$387K 0.01% 1320
2017
Q1
$284K Sell
9,600
-64,400
-87% -$1.99M 0.01% 1673
2016
Q4
$2.03M Buy
74,000
+59,400
+407% +$2.39M 0.05% 562
2016
Q3
$897K Sell
14,600
-91,300
-86% -$2.76M 0.02% 1127
2016
Q2
$2.02M Buy
105,900
+37,700
+55% +$698K 0.03% 682
2016
Q1
$1.33M Sell
68,200
-61,300
-47% -$1.07M 0.02% 935
2015
Q4
$5M Buy
129,500
+91,600
+242% +$2.97M 0.05% 500
2015
Q3
$1.22M Buy
37,900
+27,300
+258% +$926K 0.01% 1426
2015
Q2
$323K Buy
10,600
+9,200
+657% +$188K ﹤0.01% 2400
2015
Q1
$19K Sell
1,400
-190,000
-99% -$2.53M ﹤0.01% 3514
2014
Q4
$2.77M Buy
191,400
+97,300
+103% +$1.65M 0.02% 1175
2014
Q3
$1.99M Sell
94,100
-4,400
-4% -$99.3K 0.01% 1556
2014
Q2
$2.93M Buy
98,500
+2,700
+3% +$85.3K 0.01% 1335
2014
Q1
$2.3M Buy
95,800
+64,200
+203% +$1.64M 0.01% 1385
2013
Q4
$644K Buy
31,600
+9,500
+43% +$282K ﹤0.01% 2291
2013
Q3
$1.04M Buy
22,100
+200
+0.9% +$7.7K 0.01% 1869
2013
Q2
$833K Buy
+21,900
New +$783K 0.01% 2063

Other funds holding SRPT

Spot Trading's SRPT Position: Q3 2017 in Review

Spot Trading increased its Sarepta Therapeutics (SRPT) stake by 28% in Q3 2017, buying an estimated $428K and bringing the position to 48,931 shares worth $2.22M. The position accounts for 0.04% of the portfolio, ranked #672.

Spot Trading first reported a position in SRPT in Q1 2014 and has held it in 15 quarters since. The position peaked at $3.62M in Q3 2016. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

  • Spot Trading held 48,931 shares of Sarepta Therapeutics worth $2.22M as of Q3 2017.
  • Spot Trading bought 10,706 Sarepta Therapeutics shares in Q3 2017, an estimated $428K.
  • Sarepta Therapeutics made up 0.04% of Spot Trading's portfolio in Q3 2017, its #672 holding.
  • Spot Trading first reported a position in Sarepta Therapeutics in Q1 2014 and has held it in 15 quarters since.
  • Spot Trading's Sarepta Therapeutics position peaked at $3.62M in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.